The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Lysophosphatidic Acid Induces Neointima Formation Through PPARγ Activation
Open accessAbstract
Neointimal lesions are characterized by accumulation of cells within the arterial wall and are a prelude to atherosclerotic disease. Here we report that a brief exposure to either alkyl ether analogs of the growth factor–like phospholipid lysophosphatidic acid (LPA), products generated during the oxidative modification of low density lipoprotein, or to unsaturated acyl forms of LPA induce progressive formation of neointima in vivo in a rat carotid artery model. This effect is completely inhibited by the peroxisome proliferator-activated receptor (PPAR)γ antagonist GW9662 and mimicked by PPARγ agonists Rosiglitazone and 1-O-hexadecyl-2-azeleoyl-phosphatidylcholine. In contrast, stearoyl-oxovaleryl phosphatidylcholine, a PPARα agonist and polypeptide epidermal growth factor, platelet-derived growth factor, and vascular endothelial growth factor failed to elicit neointima. The structure-activity relationship for neointima induction by LPA analogs in vivo is identical to that of PPARγ activation in vitro and disparate from that of LPA G protein–coupled receptor activation. Neointima-inducing LPA analogs up-regulated the CD36 scavenger receptor in vitro and in vivo and elicited dedifferentiation of cultured vascular smooth muscle cells that was prevented by GW9662. These results suggest that selected LPA analogs are important novel endogenous PPARγ ligands capable of mediating vascular remodeling and that activation of the nuclear transcription factor PPARγ is both necessary and sufficient for neointima formation by components of oxidized low density lipoprotein.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation in atherosclerosis
Libby, P. (2002) · Nature · doi:10.1038/nature01323 · Cited by 8,315
Chawla, A., Barak, Y., Nagy, L., Liao, D., Tontonoz, P., & Evans, R. M. (2001) · Nature Medicine · doi:10.1038/83336 · Cited by 1,069 · cited 2×
“(49) that the consequence of PPAR activation may be atherogenic in some contexts and protective in others as determined by cellular context.”
BackgroundTugwood, J. D., Issemann, I., Anderson, R. G., Bundell, K. R., McPheat, W. L., & Green, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05072.x · Cited by 895
The macrophage foam cell as a target for therapeutic intervention
Li, A. C., & Glass, C. K. (2002) · Nature Medicine · doi:10.1038/nm1102-1235 · Cited by 700
Leesnitzer, L. M., Parks, D. J., Bledsoe, R. K., Cobb, J. E., Collins, J. L., Consler, T. G., Davis, R. G., Hull-Ryde, E. A., Lenhard, J. M., Patel, L., et al. (2002) · Biochemistry · doi:10.1021/bi0159581 · Cited by 566
Cited by
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Ji, R., Cheng, Y., Yue, J., Yang, J., Liu, X., Chen, H., Dean, D. B., & Zhang, C. (2007) · Circulation Research · doi:10.1161/circresaha.106.141986 · Cited by 920
Self-citationStructural and functional roles of ether lipids
Dean, J. M., & Lodhi, I. J. (2018) · Protein & Cell · doi:10.1007/s13238-017-0423-5 · Cited by 672
Peroxisomes: A Nexus for Lipid Metabolism and Cellular Signaling
Lodhi, I. J., & Semenkovich, C. F. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.002 · Cited by 605
The ins and outs of lysophosphatidic acid signaling
Moolenaar, W. H., van Meeteren, L. A., & Giepmans, B. N. G. (2004) · BioEssays · doi:10.1002/bies.20081 · Cited by 571
Llodrá, J., Angeli, V., Liu, J., Trogan, E., Fisher, E. A., & Randolph, G. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403259101 · Cited by 509
Nitrolinoleic acid. An endogenous peroxisome proliferator-activated receptor γ ligand
Schopfer, F. J., Lin, Y., Baker, P. R. S., Cui, T., Garcia-Barrio, M., Zhang, J., Chen, K., Chen, Y. E., & Freeman, B. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408384102 · Cited by 428
Pathogenesis of Systemic Sclerosis
Pattanaik, D., Brown, M., Postlethwaite, B. C., & Postlethwaite, A. E. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00272 · Cited by 405
Lysophospholipid receptors: Signalling, pharmacology and regulation by lysophospholipid metabolism
Meyer zu Heringdorf, D., & Jakobs, K. H. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.09.026 · Cited by 388
Regulation and biological activities of the autotaxin–LPA axis
van Meeteren, L. A., & Moolenaar, W. H. (2007) · Progress in Lipid Research · doi:10.1016/j.plipres.2007.02.001 · Cited by 353
CD36 in chronic kidney disease: novel insights and therapeutic opportunities
Yang, X., Okamura, D. M., Lu, X., Chen, Y., Moorhead, J., Varghese, Z., & Ruan, X. Z. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.126 · Cited by 264
PPARs and lipid ligands in inflammation and metabolism
Harmon, G. S., Lam, M. T., & Glass, C. K. (2011) · Chemical Reviews · doi:10.1021/cr2001355 · Cited by 216
Vascular involvement in systemic sclerosis (scleroderma)
Postlethwaite, Pattanaik, D., & Brown, M. (2011) · Journal of Inflammation Research · doi:10.2147/jir.s18145 · Cited by 119
Tokumura, A., Kume, T., Taira, S., Yasuda, K., & Kanzaki, H. (2009) · Molecular Human Reproduction · doi:10.1093/molehr/gap017 · Cited by 30
Metadata
- Authors
- Zhang, C., Baker, D. L., Yasuda, S., Makarova, N., Balazs, L., Johnson, L. R., Marathe, G. K., McIntyre, T. M., Xu, Y., Prestwich, G. D., Byun, H.-S., Bittman, R., & Tigyi, G.
- Venue
- The Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2004-03-08
- Volume
- 199
- Issue
- 6
- Pages
- 763-774
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2161184363
- Cited by
- 202
- References
- 5
- FWCI
- 6.34
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.